What is the current leukotriene inhibitors market size?

The leukotriene inhibitors market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the leukotriene inhibitors market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the leukotriene inhibitors market?

Key drivers include rising asthma prevalence and growing awareness of treatment options, fueling market growth.

What challenges does the leukotriene inhibitors market face?

The market faces challenges from stringent regulatory requirements and patent expirations, impacting revenue.

Which regions are leading the leukotriene inhibitors market?

North America and Europe are leading the market, driven by high healthcare expenditure and awareness.

Who are the top companies in the leukotriene inhibitors market?

Top companies include Merck, AstraZeneca, and GlaxoSmithKline, offering a range of treatment options.

What future opportunities exist in the leukotriene inhibitors market?

Future opportunities include emerging markets and novel treatments, offering growth potential for companies.

How does technology impact the leukotriene inhibitors market?

Technology advancements improve diagnosis and treatment, driving the future outlook of the leukotriene inhibitors market.

What is the current regulatory landscape for the leukotriene inhibitors market?

The regulatory landscape is complex, with stringent FDA and EMA guidelines governing market approval and sales.

leukotriene inhibitors Value Chain Analysis & Forecast Outlook 2033

leukotriene inhibitors by Application (Asthma, COPD, Allergic Rhinitis, Other), by Types (Montelukast, Zafirlukast, Proust, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $8.9 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $8.9 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

leukotriene inhibitors Market Overview

The leukotriene inhibitors market refers to the industry segment focused on the development and distribution of leukotriene inhibitors, which are medications used to treat respiratory diseases such as asthma. As the demand for effective treatments for respiratory conditions continues to rise, the leukotriene inhibitors market size is expected to experience significant growth, with a projected growth outlook and market forecast that indicates a substantial increase in industry expansion. The scope of this market encompasses various types of leukotriene inhibitors, including montelukast, zafirlukast, and pranlukast, which are used to treat asthma, allergic rhinitis, and other respiratory conditions. According to recent estimates, the current leukotriene inhibitors market size is approximately $4.8 billion.

Loading chart…

The leukotriene inhibitors market is expected to experience a compound annual growth rate (CAGR) of 7.3% during the forecast period from 2026 to 2033, driven by macro drivers such as the increasing prevalence of respiratory diseases, advancements in medical technology, and growing demand for targeted therapies. Key forces shaping the industry include technology shifts towards more efficient and targeted treatments, regulations surrounding the approval and distribution of medications, and consumer behavior trends towards more personalized healthcare. The largest region in the leukotriene inhibitors market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare spending and a growing middle class with access to advanced medical treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	8.90 million
Revenue forecast in 2033	12.37 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt plc; Sun Pharmaceutical Industries Ltd; Novartis AG; Endo Pharmaceuticals plc; Zydus Cadila; Mylan NV; Mayne Pharma Group Limited; Teva Pharmaceutical Industries Ltd; Amneal Pharmaceutical Inc; Avet Pharmaceuticals Inc; Aurobindo Pharma; GSK plc; Almirall, SA; Merck & Co.,Inc; Bausch Health; Sandoz International GmbH; Circassia Pharmaceuticals; AstraZeneca; Sanofi; McKesson Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The leukotriene inhibitors market is experiencing significant transformations, driven by various factors that impact its growth forecast and leukotriene inhibitors market size.

Growth Drivers2 items

Increasing prevalence of respiratory diseases, such as asthma, is driving the demand for leukotriene inhibitors market, leading to a substantial rise in the leukotriene inhibitors market size.

Advancements in medical technology and the development of novel leukotriene inhibitors are expanding treatment options, thereby fueling the growth forecast of the market.

Restraints2 items

Stringent regulatory frameworks and high research and development costs are hindering the growth of the leukotriene inhibitors market, affecting its overall leukotriene inhibitors market size.

The presence of generic versions of leukotriene inhibitors is increasing competition, leading to pricing pressures and limiting the growth forecast of the market.

Opportunities2 items

The growing demand for personalized medicine and targeted therapies is creating opportunities for the development of innovative leukotriene inhibitors, driving the growth forecast of the leukotriene inhibitors market.

Expanding into emerging markets and increasing awareness about leukotriene inhibitors among healthcare professionals and patients are expected to contribute to the growth of the leukotriene inhibitors market size.

Challenges2 items

The leukotriene inhibitors market faces challenges due to the high cost of leukotriene inhibitors and limited access to these medications in certain regions, impacting the overall leukotriene inhibitors market size.

The need for ongoing research and development to address the evolving needs of patients and to stay ahead of the competition is a significant challenge for companies operating in the leukotriene inhibitors market, affecting their growth forecast.

Market Segmentation

Loading chart…

The leukotriene inhibitors market can be segmented based on application, which includes asthma, allergic rhinitis, and other respiratory diseases. This segmentation contributes to the overall market size by highlighting the specific areas where leukotriene inhibitors are most effective. Understanding the application segment is crucial for leukotriene inhibitors segmentation as it enables manufacturers to tailor their products to meet the needs of specific patient groups.

In terms of types, the leukotriene inhibitors market can be divided into subtypes such as cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Each subtype has its unique mechanism of action and is used to treat specific conditions. Analyzing the types segment is essential for understanding the market taxonomy of leukotriene inhibitors, as it helps identify areas of growth and opportunities for innovation.

leukotriene inhibitors Segmentation Breakdown10 items

Application

Asthma

COPD

Allergic Rhinitis

Other

Types

Montelukast

Zafirlukast

Proust

Other

Regional Insights

Loading chart…

The leukotriene inhibitors market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of leukotriene inhibitors, favorable policies, and significant investments in healthcare infrastructure. Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure.

In Europe, key drivers include a strong ecosystem, favorable policies, and a high level of adoption. Asia Pacific is driven by increasing demographics, improving infrastructure, and growing investments in healthcare. Latin America and Middle East & Africa are expected to be driven by increasing awareness, improving infrastructure, and growing adoption. The regional forecast indicates that these regions will contribute significantly to the leukotriene inhibitors market growth.

Regional Drivers4 items

North America: mature ecosystem, high demographics awareness, established infrastructure

Europe: strong ecosystem, favorable policies, high adoption

Asia Pacific: increasing demographics, improving infrastructure, growing investments

Latin America and Middle East & Africa: increasing awareness, improving infrastructure, growing adoption

Competitive Landscape

The leukotriene inhibitors market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, and product innovation, with companies focusing on obtaining certifications and regulatory approvals to gain a competitive edge. The leukotriene inhibitors competitive landscape is characterized by high competition, with companies employing various strategies to differentiate themselves.

Companies in the market are adopting common strategies such as M&A, partnerships, and product launches to expand their presence. However, they face challenges like margin pressure, compliance costs, and commoditization, which can erode their competitive advantage. To differentiate themselves, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies have distinct strategic focuses:

Mallinckrodt plc: regional expansion

Novartis AG: innovation pipeline

Sun Pharmaceutical Industries Ltd: local manufacturing

Endo Pharmaceuticals plc: premium pricing

Zydus Cadila: OEM tie-ups

Mylan NV: vertical integration

Key leukotriene inhibitors Companies20 items

Mallinckrodt plc

Sun Pharmaceutical Industries Ltd

Novartis AG

Endo Pharmaceuticals plc

Zydus Cadila

Mylan NV

Mayne Pharma Group Limited

Teva Pharmaceutical Industries Ltd

Amneal Pharmaceutical Inc

Avet Pharmaceuticals Inc

Aurobindo Pharma

GSK plc

Almirall, SA

Merck & Co.,Inc

Bausch Health

Sandoz International GmbH

Circassia Pharmaceuticals

AstraZeneca

Sanofi

McKesson Corporation

Market Ecosystem

The leukotriene inhibitors ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. Value is created and captured as these participants interact, from the development of active pharmaceutical ingredients to the distribution and prescribing of final products. Understanding the leukotriene inhibitors ecosystem requires a comprehensive value chain analysis, examining how each segment influences the overall market.

Raw material suppliers — providing chemical components

OEMs/manufacturers — producing leukotriene inhibitors

Distributors/channel partners — delivering products to pharmacies

Regulators/standards bodies — overseeing safety and efficacy

Service providers/after-sales — offering patient support services

Data/analytics providers — supplying market insights and research

End users/buyers — patients and healthcare professionals

In the leukotriene inhibitors ecosystem, control points are largely influenced by regulators and standards bodies, as their approvals and guidelines dictate the adoption of these medications. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, including stringent regulatory requirements. Switching costs and partnerships between manufacturers and distributors can also impact the ecosystem, while regional differences in healthcare systems and patient needs may lead to variations in the leukotriene inhibitors ecosystem across different areas.

Recent Industry Insights

The leukotriene inhibitors industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as collaborations between pharmaceutical companies to advance research and development of novel leukotriene inhibitors. Additionally, there have been strategic mergers and acquisitions aimed at expanding product portfolios and strengthening market positions. Recent product launches have also been observed, with a focus on improving treatment options for patients with respiratory diseases, such as asthma. Furthermore, regulatory changes have influenced the industry, with updated guidelines for clinical trials and drug approvals. These developments are expected to shape the future of the leukotriene inhibitors market, driving growth and innovation in the sector.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the leukotriene inhibitors market outlook. The market attractiveness is moderate, driven by increasing demand for effective treatments for respiratory diseases such as asthma. The competitive intensity is high, with several key players vying for market share. The long-term outlook is promising, with ongoing innovation in the development of novel leukotriene inhibitors.

The innovation landscape is characterized by a focus on personalized medicine and the development of more targeted therapies. The demand-supply balance is expected to remain stable, with key risk factors including regulatory hurdles and patent expirations. Overall, the leukotriene inhibitors market is poised for growth, driven by increasing awareness of the importance of targeted treatments for respiratory diseases.

12 items

1. Executive Summary

2. leukotriene inhibitors Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global leukotriene inhibitors Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global leukotriene inhibitors Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global leukotriene inhibitors Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global leukotriene inhibitors Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global leukotriene inhibitors Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global leukotriene inhibitors Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global leukotriene inhibitors Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global leukotriene inhibitors Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global leukotriene inhibitors Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global leukotriene inhibitors Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global leukotriene inhibitors Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global leukotriene inhibitors Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global leukotriene inhibitors Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global leukotriene inhibitors Market Competition by Key Manufacturers

9.1. Global leukotriene inhibitors Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global leukotriene inhibitors: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Mallinckrodt plc

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sun Pharmaceutical Industries Ltd

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Novartis AG

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Endo Pharmaceuticals plc

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Zydus Cadila

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Mylan NV

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Mayne Pharma Group Limited

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Teva Pharmaceutical Industries Ltd

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Amneal Pharmaceutical Inc

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Avet Pharmaceuticals Inc

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Aurobindo Pharma

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. GSK plc

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Almirall, SA

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Merck & Co.,Inc

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Bausch Health

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Sandoz International GmbH

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Circassia Pharmaceuticals

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. AstraZeneca

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Sanofi

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. McKesson Corporation

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global leukotriene inhibitors Market

Figure 4: Global leukotriene inhibitors Market: Drivers

Figure 5: Global leukotriene inhibitors Market: Challenges

Figure 6: Global leukotriene inhibitors Market: Trends

Figure 7: Global leukotriene inhibitors Market: Opportunity

Figure 8: Global leukotriene inhibitors Market: Restraint

Figure 9: Global leukotriene inhibitors Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global leukotriene inhibitors Market Value (USD Million) By Region

Figure 19: Global leukotriene inhibitors Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global leukotriene inhibitors Market Value (USD Million) By Region

Figure 27: Global leukotriene inhibitors Market Share (%) By: Regions (2032)

Figure 28: Global leukotriene inhibitors Market Volume (K) By Region

Figure 29: Global leukotriene inhibitors Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global leukotriene inhibitors Market Value (USD Million) By Region

Figure 37: Global leukotriene inhibitors Market Share (%) By: Regions (2032)

Figure 38: Global leukotriene inhibitors Market Volume (K) By Region

Figure 39: Global leukotriene inhibitors Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

135 items

Table 1: Market Segmentation Analysis

Table 2: Global leukotriene inhibitors Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global leukotriene inhibitors Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global leukotriene inhibitors Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global leukotriene inhibitors Market Value (USD Million) By Region

Table 14: Global leukotriene inhibitors Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global leukotriene inhibitors Market Volume (K) By Region

Table 31: Global leukotriene inhibitors Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global leukotriene inhibitors Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global leukotriene inhibitors Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global leukotriene inhibitors Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Mallinckrodt plc Basic Information And Sales Area

Table 52: Mallinckrodt plc. Products Portfolio

Table 53: Sun Pharmaceutical Industries Ltd Basic Information And Sales Area

Table 54: Sun Pharmaceutical Industries Ltd. Products Portfolio

Table 55: Novartis AG Basic Information And Sales Area

Table 56: Novartis AG. Products Portfolio

Table 57: Endo Pharmaceuticals plc Basic Information And Sales Area

Table 58: Endo Pharmaceuticals plc. Products Portfolio

Table 59: Zydus Cadila Basic Information And Sales Area

Table 60: Zydus Cadila. Products Portfolio

Table 61: Mylan NV Basic Information And Sales Area

Table 62: Mylan NV. Products Portfolio

Table 63: Mayne Pharma Group Limited Basic Information And Sales Area

Table 64: Mayne Pharma Group Limited. Products Portfolio

Table 65: Teva Pharmaceutical Industries Ltd Basic Information And Sales Area

Table 66: Teva Pharmaceutical Industries Ltd. Products Portfolio

Table 67: Amneal Pharmaceutical Inc Basic Information And Sales Area

Table 68: Amneal Pharmaceutical Inc. Products Portfolio

Table 69: Avet Pharmaceuticals Inc Basic Information And Sales Area

Table 70: Avet Pharmaceuticals Inc. Products Portfolio

Table 71: Aurobindo Pharma Basic Information And Sales Area

Table 72: Aurobindo Pharma. Products Portfolio

Table 73: GSK plc Basic Information And Sales Area

Table 74: GSK plc. Products Portfolio

Table 75: Almirall, SA Basic Information And Sales Area

Table 76: Almirall, SA. Products Portfolio

Table 77: Merck & Co.,Inc Basic Information And Sales Area

Table 78: Merck & Co.,Inc. Products Portfolio

Table 79: Bausch Health Basic Information And Sales Area

Table 80: Bausch Health. Products Portfolio

Table 81: Sandoz International GmbH Basic Information And Sales Area

Table 82: Sandoz International GmbH. Products Portfolio

Table 83: Circassia Pharmaceuticals Basic Information And Sales Area

Table 84: Circassia Pharmaceuticals. Products Portfolio

Table 85: AstraZeneca Basic Information And Sales Area

Table 86: AstraZeneca. Products Portfolio

Table 87: Sanofi Basic Information And Sales Area

Table 88: Sanofi. Products Portfolio

Table 89: McKesson Corporation Basic Information And Sales Area

Table 90: McKesson Corporation. Products Portfolio

Table 91: Global Market Value (USD Million) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Market Value (USD Million) (2025-2032) By Types

Table 94: Global Market Share (%) By Types (2032)

Table 95: Global Market Volume (K) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Market Volume (K) (2025-2032) By Types

Table 98: Global Market Share (%) By Types (2032)

Table 99: Global leukotriene inhibitors Market Value (USD Million) By Region

Table 100: Global leukotriene inhibitors Market Share (%) By Region (2025-2032)

Table 101: North America Market Value (USD Million) (2025-2032) By Country

Table 102: North America Market Value (USD Million) (2025-2032) By Application

Table 103: North America Market Value (USD Million) (2025-2032) By Types

Table 104: Europe Market Value (USD Million) (2025-2032) By Country

Table 105: Europe Market Value (USD Million) (2025-2032) By Application

Table 106: Europe Market Value (USD Million) (2025-2032) By Types

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 108: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 110: South America Market Value (USD Million) (2025-2032) By Country

Table 111: South America Market Value (USD Million) (2025-2032) By Application

Table 112: South America Market Value (USD Million) (2025-2032) By Types

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 114: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 116: Global leukotriene inhibitors Market Volume (K) By Region

Table 117: Global leukotriene inhibitors Market Share (%) By Region (2025-2032)

Table 118: North America Market Volume (K) (2025-2032) By Country

Table 119: North America Market Volume (K) (2025-2032) By Application

Table 120: North America Market Volume (K) (2025-2032) By Types

Table 121: Europe Market Volume (K) (2025-2032) By Country

Table 122: Europe Market Volume (K) (2025-2032) By Application

Table 123: Europe Market Volume (K) (2025-2032) By Types

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 125: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 127: South America Market Volume (K) (2025-2032) By Country

Table 128: South America Market Volume (K) (2025-2032) By Application

Table 129: South America Market Volume (K) (2025-2032) By Types

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 131: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 133: Research Programs/Design For This Report

Table 134: Key Data Information From Secondary Sources

Table 135: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

leukotriene inhibitors Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.90 million
Revenue forecast in 2033	12.37 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mallinckrodt plc; Sun Pharmaceutical Industries Ltd; Novartis AG; Endo Pharmaceuticals plc; Zydus Cadila; Mylan NV; Mayne Pharma Group Limited; Teva Pharmaceutical Industries Ltd; Amneal Pharmaceutical Inc; Avet Pharmaceuticals Inc; Aurobindo Pharma; GSK plc; Almirall, SA; Merck & Co.,Inc; Bausch Health; Sandoz International GmbH; Circassia Pharmaceuticals; AstraZeneca; Sanofi; McKesson Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The leukotriene inhibitors market is experiencing significant transformations, driven by various factors that impact its growth forecast and leukotriene inhibitors market size.

Growth Drivers2 items

Advancements in medical technology and the development of novel leukotriene inhibitors are expanding treatment options, thereby fueling the growth forecast of the market.

Restraints2 items

The presence of generic versions of leukotriene inhibitors is increasing competition, leading to pricing pressures and limiting the growth forecast of the market.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

leukotriene inhibitors Segmentation Breakdown10 items

Application

Asthma

COPD

Allergic Rhinitis

Other

Types

Montelukast

Zafirlukast

Proust

Other

Regional Insights

Loading chart…

Regional Drivers4 items

North America: mature ecosystem, high demographics awareness, established infrastructure

Europe: strong ecosystem, favorable policies, high adoption

Asia Pacific: increasing demographics, improving infrastructure, growing investments

Latin America and Middle East & Africa: increasing awareness, improving infrastructure, growing adoption

Competitive Landscape

Mallinckrodt plc: regional expansion

Novartis AG: innovation pipeline

Sun Pharmaceutical Industries Ltd: local manufacturing

Endo Pharmaceuticals plc: premium pricing

Zydus Cadila: OEM tie-ups

Mylan NV: vertical integration

Key leukotriene inhibitors Companies20 items

Mallinckrodt plc

Sun Pharmaceutical Industries Ltd

Novartis AG

Endo Pharmaceuticals plc

Zydus Cadila

Mylan NV

Mayne Pharma Group Limited

Teva Pharmaceutical Industries Ltd

Amneal Pharmaceutical Inc

Avet Pharmaceuticals Inc

Aurobindo Pharma

GSK plc

Almirall, SA

Merck & Co.,Inc

Bausch Health

Sandoz International GmbH

Circassia Pharmaceuticals

AstraZeneca

Sanofi

McKesson Corporation

Market Ecosystem

Raw material suppliers — providing chemical components

OEMs/manufacturers — producing leukotriene inhibitors

Distributors/channel partners — delivering products to pharmacies

Regulators/standards bodies — overseeing safety and efficacy

Service providers/after-sales — offering patient support services

Data/analytics providers — supplying market insights and research

End users/buyers — patients and healthcare professionals

Recent Industry Insights

Analyst Overview

Table of Contents